Revolutionary Discovery Opens the Door to New Treatments for COVID-19 and Alzheimer's - Jordan News
Scientists have made a groundbreaking discovery in understanding autoimmune diseases, potentially opening the door to new treatments for conditions like COVID-19 and Alzheimer's disease. اضافة اعلان Researchers from the University of Washington and the University of Pennsylvania have made a scientific breakthrough that could change the future of medicine by unveiling the protein ArfGAP2, which plays a crucial role in regulating immune responses. This important discovery came by chance while studying a rare disease known as vascular inflammation associated with the Stimulator of Interferon Genes (STING) protein, which affects one child in every million and causes the immune system to attack healthy tissues, especially in the lungs and extremities. This disease is often fatal before reaching adulthood, resulting from excessive activity of the STING protein, which is supposed to help the body detect viral DNA and trigger immune responses. However, in cases of vascular inflammation associated with STING, this protein remains constantly active, leading to chronic immune responses and tissue damage. The scientists found that this protein acts as a critical link between immune system activation and the release of inflammatory substances. Through a series of precise experiments, the research team demonstrated that disabling this protein in mice with vascular inflammation associated with STING completely halted tissue damage, potentially paving the way for developing new treatments for autoimmune diseases. What's even more exciting is that these results could extend to common diseases like COVID-19 and Alzheimer's, where inflammation plays a key role in their development. To explain how it works, the researchers used a powerful analogy, describing the discovered protein as the "traffic controller at a train station," which regulates the release of "trains" (inflammatory substances) from immune cells. Without this controller, the harmful inflammatory process halts while preserving beneficial immune functions. This new understanding represents a significant shift in immunology, as it provides the long-missing link in understanding how the immune system shifts from being a protector to attacking the body itself.
Currently, the team is working on developing drug molecules that specifically target this protein, with clinical trials expected to begin within the next three years. If successful, these efforts could spark a real revolution in the treatment of a wide range of diseases affecting millions worldwide, from rheumatoid arthritis to multiple sclerosis, and potentially even some neurodegenerative diseases.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Ammon
18-05-2025
- Ammon
US clears first blood test for Alzheimer's detection
Ammon News - The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the regulator said on Friday, making the device the first of its kind to detect the brain-wasting condition. Blood tests could speed up diagnosis of the disease and make it easier for more people to access its treatments such as Biogen and Eisai's Leqembi and Eli Lilly's Kisunla, since traditional tests are often costly or uncomfortable. Fujirebio's test, branded as Lumipulse, checks for two proteins in the blood and uses their ratio to help detect signs of amyloid beta plaque, considered a hallmark of the disease, in the brain. Other options to detect Alzheimer's include procedures such as a spinal tap, which requires an invasive puncture to collect spinal fluid, or an expensive PET brain scan that may not be reimbursed by health insurers. "Street expectations for both therapies (Leqembi and Kisunla) are modest" with a slow ramp over the next few years, given the lack of access to neurologists, said Citi analyst Geoffrey Meacham. "An approved blood-based diagnostic is a positive in a disease area that has been starved of game-changing innovation." Biogen has been doubling down on Leqembi but it has failed to live up to lofty expectations due to concerns over cost, efficacy and side effects. In the first quarter, Leqembi brought $96 million in sales, while Lilly recorded $21.5 million in Kisunla sales. Lumipulse and C2N Diagnostics' PrecivityAD2 were the top two performers when compared with four other commercial blood tests for Alzheimer's, according to a study led by researchers at Washington University School of Medicine.
Roya News
01-05-2025
- Roya News
China pushes back, claims COVID-19 may have started in US
China has reiterated its claim that COVID-19 may have originated in the US, challenging the US narrative in a newly published white paper detailing Beijing's pandemic response. The document was released Wednesday through the state-run Xinhua news agency, shortly after the White House reasserted its belief that the virus stemmed from a laboratory in China. The Trump administration recently launched a new government website on April 18, outlining its position that the coronavirus leaked from a Chinese lab. The page also criticizes former US President Joe Biden, former National Institute of Allergy and Infectious Diseases (NIAID) Director Dr. Anthony Fauci, and the World Health Organization (WHO) for what it describes as mishandling the early stages of the pandemic. In its white paper, Beijing accused Washington of politicizing the virus's origin and referenced a Missouri lawsuit in which China was ordered to pay USD 24 billion for allegedly stockpiling protective medical equipment and covering up the initial outbreak. China defended its own transparency, insisting it had 'shared relevant information with the WHO and the international community in a timely manner,' and pointed to a joint WHO-China study that concluded a lab leak was 'extremely unlikely.' 'The US should not continue to 'pretend to be deaf and dumb,' but should respond to the legitimate concerns of the international community,' the white paper said. The Chinese report also claimed there is 'substantial evidence' suggesting the virus may have first appeared in the US, potentially even before the official Chinese timeline. Although the CIA updated its stance in January to say a lab origin in China was more likely than a natural emergence, it did so with 'low confidence' and acknowledged that both theories remain viable.
Jordan News
29-04-2025
- Jordan News
Iron Levels May Explain Brain Fog During Menopause - Jordan News
New research from the University of Oklahoma sheds light on an underexplored scientific area: the relationship between iron levels in the blood and cognitive performance in women undergoing menopause. اضافة اعلان Cognitive Function Improves with Sufficient Iron Levels During Menopause The findings offer encouraging news for women experiencing brain fog and other symptoms. The study revealed that women with sufficient iron levels in their blood during menopause demonstrated better cognitive performance. Importantly, having adequate iron levels in the blood does not mean dangerously high iron levels in the brain—a key distinction, as excess brain iron has been linked to a greater risk of neurodegenerative diseases like Alzheimer's. 'When a woman reaches menopause, she stops losing blood monthly, which means she's no longer losing iron,' said lead researcher Michael Wenger. According to Medical Xpress, the research team measured blood iron levels, conducted MRI scans to assess brain iron, and evaluated cognitive performance using behavioral tests. While none of the women in the study were clinically iron deficient, many had iron levels lower than the expected range for their age. These women performed worse on measures of memory, attention, and cognition. This finding was both surprising and positive: having iron levels that meet or slightly exceed age-based expectations does not seem to increase brain iron accumulation. What Does Iron Deficiency Mean? Iron deficiency is not the same as anemia. Wenger clarified that while low iron can be a risk factor for anemia, anemia itself can result from various causes. 'Our previous research has shown that iron deficiency can have significant cognitive costs,' Wenger said. 'Low iron may be one reason women experience mental fog during menopause.' Changes in Vision The study also points to a possible reason some women report changes in vision during menopause. Iron plays a crucial role in the synthesis of the neurotransmitter dopamine, which is essential for transmitting light signals in the eye. Iron Supplements Although iron supplements are generally not the first-line solution due to their potential gastrointestinal side effects, Wenger notes that low-dose supplements or dietary changes to increase iron intake may be beneficial.
